Granulocyte-macrophage-colony-stimulating factor: a review from preclinical development to clinical application.
Neumanaitis
J
J
West Penn Hospital, Western Pennsylvania Cancer Institute, Pittsburgh.
D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D016026:Bone Marrow Transplantation; D001943:Breast Neoplasms / Q000601:surgery; D002986:Clinical Trials as Topic; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000601:surgery; D008223:Lymphoma / Q000601:surgery; D009190:Myelodysplastic Syndromes / Q000628:therapy; D009503:Neutropenia / Q000139:chemically induced / Q000628:therapy*; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor